Breakeven Date Change • Jul 01
Forecast to breakeven in 2025 The 4 analysts covering Diurnal Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£7.56m in 2025. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Price Target Changed • Apr 27
Price target decreased to UK£1.24 Down from UK£1.52, the current price target is an average from 5 analysts. New target price is 762% above last closing price of UK£0.14. Stock is down 79% over the past year. The company is forecast to post a net loss per share of UK£0.10 next year compared to a net loss per share of UK£0.073 last year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Jean-Michel Yves Cossery was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Apr 01
Price target decreased to UK£1.24 Down from UK£1.60, the current price target is an average from 5 analysts. New target price is 673% above last closing price of UK£0.16. Stock is down 81% over the past year. The company is forecast to post a net loss per share of UK£0.095 next year compared to a net loss per share of UK£0.073 last year. Price Target Changed • Mar 23
Price target decreased to UK£1.52 Down from UK£1.66, the current price target is an average from 5 analysts. New target price is 883% above last closing price of UK£0.15. Stock is down 78% over the past year. The company is forecast to post a net loss per share of UK£0.091 next year compared to a net loss per share of UK£0.073 last year. Breakeven Date Change • Jan 18
No longer forecast to breakeven The 5 analysts covering Diurnal Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£12.4m in 2024. New consensus forecast suggests the company will make a loss of UK£18.0m in 2024. Breakeven Date Change • Dec 15
No longer forecast to breakeven The 5 analysts covering Diurnal Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£12.4m in 2024. New consensus forecast suggests the company will make a loss of UK£12.0m in 2024. Price Target Changed • Nov 27
Price target decreased to UK£1.66 Down from UK£1.87, the current price target is an average from 4 analysts. New target price is 184% above last closing price of UK£0.58. Stock is up 17% over the past year. The company is forecast to post a net loss per share of UK£0.085 next year compared to a net loss per share of UK£0.073 last year. Reported Earnings • Sep 15
Full year 2021 earnings released: UK£0.073 loss per share (vs UK£0.043 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: UK£4.37m (down 31% from FY 2020). Net loss: UK£10.0m (loss widened 147% from FY 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jul 16
CFO, Company Secretary & Director recently sold UK£67k worth of stock On the 13th of July, Richard Bungay sold around 106k shares on-market at roughly UK£0.63 per share. This was the largest sale by an insider in the last 3 months. Richard has been a seller over the last 12 months, reducing personal holdings by UK£62k. Breakeven Date Change • Jul 02
Forecast to breakeven in 2024 The 4 analysts covering Diurnal Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of UK£40.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Price Target Changed • Mar 26
Price target increased to UK£1.25 Up from UK£0.94, the current price target is an average from 4 analysts. New target price is 40% above last closing price of UK£0.89. Stock is up 178% over the past year. Major Estimate Revision • Mar 26
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from UK£3.06m to UK£3.53m. EPS estimate unchanged from -UK£0.086 at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 2.3% next year. Consensus price target of UK£0.97 unchanged from last update. Share price rose 38% to UK£0.89 over the past week. Is New 90 Day High Low • Mar 15
New 90-day high: UK£0.67 The company is up 38% from a price of UK£0.48 on 15 December 2020. Outperformed the British market which is up 5.0% over the last 90 days. Exceeded the Biotechs industry, which is up 24% over the same period. Reported Earnings • Feb 25
First half 2021 earnings released: UK£0.037 loss per share (vs UK£0.047 loss in 1H 2020) The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: UK£1.21m (up 5.8% from 1H 2020). Net loss: UK£4.66m (loss widened 16% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jan 18
Analysts update estimates The 2021 consensus revenue estimate was lowered from UK£5.62m to UK£4.76m. Earning per share (EPS) estimate was unchanged from the last update at -UK£0.066. The Biotechs industry in the United Kingdom is expected to see an average net income growth of 4.1% next year. The consensus price target of UK£0.94 was unchanged from the last update. Share price stayed mostly flat at UK£0.62 over the past week. Is New 90 Day High Low • Jan 13
New 90-day high: UK£0.66 The company is up 6.0% from its price of UK£0.62 on 15 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.54 per share. Price Target Changed • Nov 20
Price target lowered to UK£0.88 Down from UK£0.96, the current price target is an average from 2 analysts. The new target price is 68% above the current share price of UK£0.53. As of last close, the stock is up 59% over the past year. Is New 90 Day High Low • Nov 18
New 90-day low: UK£0.53 The company is down 9.0% from its price of UK£0.58 on 20 August 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.44 per share. Reported Earnings • Oct 10
Full year earnings released - UK£0.043 loss per share Over the last 12 months the company has reported total losses of UK£4.07m, with losses narrowing by 67% from the prior year. Total revenue was UK£6.31m over the last 12 months, up by UK£5.26m from the prior year. Analyst Estimate Surprise Post Earnings • Oct 10
Annual earnings released: Revenue and earnings beat expectations Annual revenue exceeded analyst estimates by 164% at UK£6.31m. Earnings per share (EPS) also surpassed analyst estimates by 34% at -UK£0.043. Revenue is expected to shrink by 3.7% over the next year, compared to a 50% growth forecast for the Biotechs industry in the United Kingdom. Major Estimate Revision • Oct 01
Analysts increase revenue estimates to UK£6.08m The 2021 consensus revenue estimate increased from UK£4.70m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -UK£0.044 to -UK£0.032 for the same period. The Biotechs industry in the United Kingdom is expected to see an average net income growth of 11% next year. The consensus price target increased from UK£0.84 to UK£0.96. Share price is down by 14% to UK£0.65 over the past week. Price Target Changed • Sep 30
Price target raised to UK£0.96 Up from UK£0.84, the current price target is an average from 2 analysts. The new target price is 49% above the current share price of UK£0.65. As of last close, the stock is up 164% over the past year. Is New 90 Day High Low • Sep 19
New 90-day high: UK£0.65 The company is up 81% from its price of UK£0.36 on 19 June 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 